Salvianolic Acid B Inhibits ERK and p38 MAPK Signaling in TGF-β1-Stimulated Human Hepatic Stellate Cell Line (LX-2) via Distinct Pathways

被引:34
作者
Lv, Zhigang [1 ,2 ,3 ]
Xu, Lieming [1 ,2 ,4 ,5 ]
机构
[1] Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Shanghai 201203, Peoples R China
[2] Shanghai Univ Tradit Chinese Med, Inst Liver Dis, Shanghai 201203, Peoples R China
[3] Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA
[4] Shanghai Univ Tradit Chinese Med, Key Lab Liver & Kidney Dis, Minist Educ, Shanghai 200444, Peoples R China
[5] Shanghai Univ, E Inst Tradit Chinese Med Internal Med, Shanghai 201203, Peoples R China
基金
上海市自然科学基金;
关键词
ACTIVATED PROTEIN-KINASE; LIVER FIBROSIS; CROSS-TALK; SMAD; EXPRESSION; TGF-BETA-1; CYTOKINES; TARGETS; PAI-1;
D O I
10.1155/2012/960128
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Salvianolic acid B (SA-B) is water-soluble component of Radix Salvia miltiorrhiza. The previous work indicated that SA-B can inhibit MAPK and Smad signaling in activated hepatic stellate cells (HSCs) to performanti-fibrotic activity Lv et al. 2010. However, some studies have shown that there is cross-talk between MAPK and Smad in certain cell types. Thus, the anti-fibrotic action of SA-B may be through the cross-talk. In order to clarify the mechanism of SA-B further, we knocked down Smad in LX-2 cells (SRV4) via RNAi, and then added TGF-beta 1, and PD98059 or SB203580 and SA-B. The levels of p-MEK and p-p38 were inhibited by SA-B in SRV4 independent of TGF-beta 1. The expression of Col I and alpha-SMA in SRV4 could be reduced by SA-B independent TGF-beta 1. SB203580 had not significant effect on p-MEK in SRV4 stimulated by TGF-beta 1. The levels of p-MEK in SRV4 were not increased significantly after TGF-beta 1 stimulation. PD98059 had no effect on the levels of p-p38 in SRV4 irrespective of TGF-beta 1. In conclusion, SA-B inhibits the synthesis of Col I in LX-2 cells independent of TGF-beta 1 stimulation, and the anti-fibrotic effect of SA-B is due to direct inhibition of p38 signaling and inhibition the cross-talk of Smad to ERK signaling.
引用
收藏
页数:11
相关论文
共 23 条
[1]   TGF-β1 targets the GSK-3β/β-catenin pathway via ERK activation in the transition of human lung fibroblasts into myofibroblasts [J].
Caraci, Filippo ;
Gili, Elisa ;
Calafiore, Marco ;
Failla, Marco ;
La Rosa, Cristina ;
Crimi, Nunzio ;
Sortino, Maria Angela ;
Nicoletti, Ferdinando ;
Copani, Agata ;
Vancheri, Carlo .
PHARMACOLOGICAL RESEARCH, 2008, 57 (04) :274-282
[2]   The role of TGF-β1 and cytokines in the modulation of liver fibrosis by Sho-saiko-to in rat's bile duct ligated model [J].
Chen, MH ;
Chen, JC ;
Tsai, CC ;
Wang, WC ;
Chang, DC ;
Tu, DG ;
Hsieh, HY .
JOURNAL OF ETHNOPHARMACOLOGY, 2005, 97 (01) :7-13
[3]   Liver fibrosis: from mechanisms to treatment [J].
Friedman, Scott L. .
GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2007, 31 (10) :812-814
[4]   Human and rat hepatic stellate cells produce stem cell factor:: a possible mechanism for mast cell recruitment in liver fibrosis [J].
Gaça, MDA ;
Pickering, JA ;
Arthur, MJP ;
Benyon, RC .
JOURNAL OF HEPATOLOGY, 1999, 30 (05) :850-858
[5]   Cross-talk between ERK MAP kinase and Smad-signaling pathways enhances TGF-β dependent responses in human mesangial cells [J].
Hayashida, T ;
deCaestecker, M ;
Schnaper, HW .
FASEB JOURNAL, 2003, 17 (09) :1576-+
[6]   ERK contributes to the effects of Smad signaling on oxidized LDL-induced PAI-1 expression in human mesangial cells [J].
Hong, Hye Kyoung ;
Song, Chi Young ;
Kim, Bong Cho ;
Lee, Hyun Soon .
TRANSLATIONAL RESEARCH, 2006, 148 (04) :171-179
[7]  
Hu YY, 1997, ACTA PHARMACOL SIN, V18, P478
[8]   TGF-β1 in liver fibrosis:: an inducible transgenic mouse model to study liver fibrogenesis [J].
Kanzler, S ;
Lohse, AW ;
Keil, A ;
Henninger, J ;
Dienes, HP ;
Schirmacher, P ;
Rose-John, S ;
Zum Büschenfelde, KHM ;
Blessing, M .
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 1999, 276 (04) :G1059-G1068
[9]   p38 map kinases: Key signalling molecules as therapeutic targets for inflammatory diseases [J].
Kumar, S ;
Boehm, J ;
Lee, JC .
NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (09) :717-726
[10]  
Liu Chenghai, 2002, Zhonghua Yi Xue Za Zhi, V82, P1267